Cancer associated inflammation and the host immune response are key determinants of progression and outcome in solid malignancies. There is now persuasive evidence that inflammation is key to tumourigenesis via dna damage, stimulation of angiogenesis and proliferation, and inhibition of apoptosis. there have long been suspicions that dysregulated immune and inflammatory responses promote the progression and dissemination of established cancers and there is a heightened risk of cancer development in individuals with chronic inflammatory diseases. the tumour microenvironment is now viewed as a battleground for pro-tumour and anti-tumour responses. We now see an increase array of novel therapeutic targets targeting innate and adaptive components of the immune response to cancer. ONCO-Immunology with immunotherapy are an established part of clinical practice differing from conventional anti-cancer treatments in that the strategies do not principally target cancer cells. This talk will focus on the evidence that inflammation influences malignant progression in gi malignancy discussing novel therapeutic strategies.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7859